News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase III
Boehringer Ingelheim Release: Efficacy Of Ofev (Nintedanib) Reinforced In Range Of Patients With IPF In New Analyses Presented At CHEST 10/24/2016
CytoDyn (CYDY) Files Protocol For Extended Access To PRO 140 For Patients Who Reach The End Of PRO 140 Pivotal Phase III Trial 10/24/2016
Gilead (GILD) Touts 2-Year Late-Stage Descovy-Truvada HIV Data 10/24/2016
Inovio Pharma (INO) Shares Crash as the FDA Places Hold on Its Phase III HPV Program 10/24/2016
How 3 Huge Discoveries in 2016 are Moving Us Closer to a Breast Cancer Cure 10/24/2016
Faron Pharmaceuticals Ltd. Release: First Traumakine Phase III Patient In Japan Recruited For The Treatment Of Acute Respiratory Distress Syndrome And Update On Pan-European Phase III Traumakine Trial 10/24/2016
Alzheon Publishes New Analyses From Phase III Studies Showing Clinical Benefit Of Tramiprosate In Alzheimer’s Patients Who Are Carriers Of APOE4, The Major Genetic Risk Factor In Up To 65 Percent Of Alzheimer’s Patients 10/24/2016
Gilead (GILD) Presents Results From Phase 3 Studies Evaluating Switching To Descovy (FTC/TAF)-Based Regimens From Truvada (FTC/TDF)-Based Regimens 10/24/2016
Boston Biomedical Initiates Canstem303c: A Global Phase III Study Investigating Cancer Stemness Inhibitor Napabucasin In Patients With Pretreated Advanced Colorectal Cancer 10/21/2016
CEL-SCI (CVM) Provides Update On Partial Clinical Hold On Phase III Clinical Trial 10/21/2016
Amgen (AMGN)'s Xgeva Meets Primary Endpoints in Late-Stage Study, Secondary Endpoints Missed 10/21/2016
Study Stopped Early as Merck & Co. (MRK)'s Immunotherapy Drug Wows in Bladder Cancer Trial 10/21/2016
Alkermes (ALKS) Rockets as Depression Drug Aces Key Late-Stage Trial 10/21/2016
Rigel (RIGL)'s Bleeding Disorder Drug Flunks Phase III Test, Stock Tanks 10/20/2016
Theravance Biopharma (TBPH) And Mylan (MYL) Announce Positive Results From Two Pivotal Phase 3 Studies Of Revefenacin (TD-4208) For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD) 10/20/2016
Dipexium Pharmaceuticals (DPRX) Provides Update On Availability Of Results From Pivotal Phase 3 Clinical Trials With Locilex 10/20/2016
MicuRx Pharma Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA 10/20/2016
Gilead (GILD) Announces SVR12 Rates From Four Phase III Studies Of A Once-Daily, Fixed-Dose Combination Of Sofosbuvir, Velpatasvir And Voxilaprevir In Treatment-Naïve And Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients 10/20/2016
Seattle Genetics (SGEN) Demonstrates Commitment To Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations At ISHL 2016 10/20/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Receives Positive Nice Recommendation For Adults With Chronic Plaque Psoriasis 10/20/2016
AbbVie (ABBV) Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At American Society for Reproductive Medicine Scientific Congress 10/19/2016
PAION AG: Positive Remimazolam Phase III Colonoscopy Results Presented At The 2016 American College of Gastroenterology Annual Scientific Meeting 10/19/2016
Daiichi Sankyo and Plexxikon Suspend Phase III Trial of Drug for Rare Tendon Cancer 10/19/2016
Merck & Co. (MRK)'s CMV Drug Passes Clinical Endpoints in Phase III Trial 10/19/2016
How Pfizer (PFE) is Quietly Rebuilding Its Alzheimer's Pipeline 10/19/2016
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes? 10/18/2016
Cytokinetics (CYTK) Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv 10/18/2016
PharmaEngine, Inc. Announces Onivyde Receives European Marketing Authorization For The Treatment Of Metastatic Adenocarcinoma Of The Pancreas Following Gemcitabine Based Therapy 10/18/2016
Ritter Pharmaceuticals, Inc. Concludes Last Patient Visit Of Its Phase 2b/3 Clinical Trial Of RP-G28 For The Treatment Of Lactose Intolerance 10/18/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical 10/18/2016
Actinium (ATNM.OB) Granted Orphan Designation From The EMA For Iomab-B 10/18/2016
Takeda (TKPYY) Showcases Continued Commitment In Hodgkin Lymphoma During 10th International Symposium On Hodgkin Lymphoma (ISHL) 10/18/2016
Shire (SHPG) Granted EU Marketing Authorization Of Onivyde, In Combination With 5-Fluorouracil (5-FU) And Leucovorin (LV),For The Treatment Of Metastatic Adenocarcinoma Of The Pancreas In Adult Patients Who Have Progressed Following Gemcitabine-Based Therapy 10/18/2016
PharmaMar Completes The Patient Recruitment For The "CORAIL" Phase III Pivotal Study With PM1183 10/18/2016
A Look at CRISPR, 'Biotech's Biggest Discovery of the Century,' and the 3 Companies Knee Deep in It 10/17/2016
All Eyes on Eli Lilly (LLY)'s Large-Scale Alzheimer's Trial 10/17/2016
Watch Out, Ionis Pharma (IONS): Could This Little Biotech’s Experimental SMA Treatment Be a Threat? 10/17/2016
Synergy Pharma Presents Long-Term Data For Plecanatide In Chronic Idiopathic Constipation At The American College of Gastroenterology Annual Scientific Meeting 10/17/2016
Boehringer Ingelheim Release: New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk 10/17/2016
Teva (TEVA) Receives Positive Opinion From EMA'S Committee For Medicinal Products For Human Use (CHMP) To Extend Indication Of Trisenox For First Line Treatment Of Low- To Intermediate Risk Acute Promyelocytic Leukemia (APL) 10/17/2016
Ferring Pharma Receives Positive CHMP Opinion For REKOVELLE (Follitropin Delta) 10/17/2016
3 Healthcare Giants Are All Trying to Take a Bite Out of AbbVie (ABBV)'s Humira Domination 10/14/2016
3 Biotechs With Cancer Drugs That Could Win Approval in 2017 10/14/2016
TG Therapeutics, Inc. (MHA) Stock Plunges as Company Modifies Phase III Cancer Trial Protocols 10/14/2016
Intercept Pharma (ICPT) Gains Positive CHMP Opinion for Ocaliva 10/14/2016
EMA Committee Conditionally Approves AbbVie (ABBV)'s Leukaemia Drug VENCLYXTO 10/14/2016
TetraPhase (TTPH) Doses First Patient In IGNITE4 Phase 3 Clinical Trial Of Eravacycline In cIAI 10/14/2016
ESMO 2016 Takeaways: Don't Miss Celldex (CLDX), Exelixis (EXEL) and Tesaro (TSRO) 10/13/2016
Allergan (AGN)'s BELKYRA (Deoxycholic Acid) Receives Marketing Authorisation In Sweden For The Treatment Of Moderate To Severe Fullness Under The Chin (Double Chin) 10/13/2016
Starpharma Release: Enrolment Complete For Phase 3 VivaGel BV-R Program 10/13/2016
OncoGenex (OGXI) Announces Results From the Phase III ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer 10/13/2016
Esperion (ESPR) Release: Bempedoic Acid Global Phase 3 Clinical Program To Include Patients On Any Statin At Any Dose 10/13/2016
bluebird bio (BLUE) Provides Update On Lentiglobin Programs And Research And Development Strategy At Gene Therapy Day 10/13/2016
Delcath Systems (DCTH) Announces First European Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases 10/12/2016
AMAG (AMAG) Announces Achievement Of Key Milestones In Next Generation Development Programs For Makena And Feraheme 10/12/2016
Daiichi Sankyo Announces First Patient Enrolled In Phase 3 QuANTUM-First Trial Investigating Quizartinib In Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia 10/11/2016
Merrimack (MACK) Release: Final Results Of NAPOLI-1 Study Confirm Overall Survival And Progression-Free Survival Benefit For The ONIVYDE Regimen For Patients With Metastatic Pancreatic Cancer 10/11/2016
Delcath Systems (DCTH) Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases 10/11/2016
Advanced Accelerator Applications Announces Presentations On Lutathera NETTER-1 Phase III And Neobomb1 At EANM 10/11/2016
Novartis AG (NVS)-Backed Gamida Cell Nabs Breakthrough Tag for NiCord 10/11/2016
Provectus Announces Poster Presentation On PV-10 At European Society Of Medical Oncology 2016 Congress Now Available Online 10/11/2016
Tesaro (TSRO) Jumped on PARP Ovarian Cancer Win Vs. AstraZeneca PLC (AZN), AbbVie (ABBV) 10/11/2016
A Look at This Tiny Massachusetts Biotech That Could Take Down Alzheimer's 10/11/2016
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study 10/10/2016
Regeneron (REGN) Could Have Another Blockbuster in This Drug 10/10/2016
Genentech (RHHBY) Scores Another Win as Tecentriq Succeeds in Late-Stage Lung Cancer Trial 10/10/2016
Beaten-Down Alnylam (ALNY) Says Patisiran Trial Can Continue Following Revusiran Halt 10/10/2016
Alnylam (ALNY) Release: Data Monitoring Committee Recommends Continuation Of APOLLO Phase 3 Clinical Trial Of Patisiran For Hereditary ATTR Amyloidosis With Polyneuropathy (hATTR-PN) 10/10/2016
Pfizer (PFE) Release: First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT (sunitinib) Extended Disease Free Survival After Surgical Removal 10/10/2016
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Shows Durable Response in Longest Follow-up for a PD-1 Inhibitor in Previously Treated Advanced Non-Small Cell Lung Cancer 10/10/2016
Boehringer Ingelheim Release: Phase III Nintedanib Trial Results In Patients With Metastatic Colorectal Cancer Announced At ESMO 10/10/2016
Peregrine (PPHM) Reports Top-Line And Initial Biomarker Data From Phase III SUNRISE Trial Of Bavituximab In Oral Presentation At European Society For Medical Oncology (ESMO) 2016 Congress 10/10/2016
Genmab A/S (GEN.CO) Release: U.S. FDA Grants Priority Review For Daratumumab In Relapsed Multiple Myeloma 10/10/2016
The Race For PARP, A New Class Of Ovarian Cancer Drugs, Heats Up 10/10/2016
4 Small Biotechs That Could Give Gilead (GILD), Merck & Co. (MRK) Pfizer (PFE) Some Competition With NASH 10/7/2016
This Experimental Drug Could be Johnson & Johnson (JNJ)'s Next Blockbuster 10/7/2016
Update from Alcobra (ADHD) On Recent FDA Communications 10/7/2016
Celgene (CELG) Release: Data Presented At ESMO 2016 Adds To Understanding Of Abraxane As A Therapy For Patients With Historically Challenging Solid Tumors 10/7/2016
Flamel Technologies (FLML) Reaches Agreement With FDA On Protocol For Phase III Pivotal Trial Of FT218 10/7/2016
Alexion (ALXN) Release: New Long-Term Data Presented At WCPGHAN 2016 Show Rapid And Sustained Improvements In Important Markers Of Liver Injury And Lipid Abnormalities In Children And Adults With Lysosomal Acid Lipase Deficiency (LAL-D) Treated With Kanuma (Sebelipase Alfa) 10/7/2016
Q Biomed Comments On Its Glaucoma Drug And Industry News In The Ophthalmology Space 10/7/2016
CytoDyn (CYDY) Announces Favorable Protocol Modifications For Pivotal Phase III Combination Trial With PRO 140 After Positive FDA Meeting 10/6/2016
CoLucid Pharma (CLCD) Announces Additional Analyses Of Lasmiditan’s Onset Of Action Data From SAMURAI And Supporting Non-Clinical Data 10/6/2016
Aurinia (ISA.TO) Releases Open-Label AURION Data Demonstrating Increased Remission Rates Over Time For Voclosporin In The Treatment Of Lupus Nephritis 10/6/2016
RedHill Biopharma (RDHL) Provides Progress Update On RHB-104 Phase III Crohn’s Disease Program And Introduces Option For Early Stop For Success In Q2/2017 10/6/2016
A Closer Look at the Pipelines Pfizer (PFE) Inherited From Recent Acquisitions 10/5/2016
FDA Grants Breakthrough Therapy Designation For Genentech (RHHBY)’s Actemra (Tocilizumab) In Giant Cell Arteritis, A Form Of Vasculitis 10/5/2016
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status 10/5/2016
Vtesse Announces Dosing Of First Patient In Germany For Phase 2b/3 Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 10/5/2016
Tenax Therapeutics (TENX) Provides Clinical Update For Lead Candidate Levosimendan 10/5/2016
Hanyang University Guri Hospital: CIK Treatment Extends Progression-free Survival Of Glioblastoma Patients By 1.5 Times 10/5/2016
Chugai Pharma's ACTEMRA/RoACTEMRA Receives Breakthrough Therapy Designation From U.S. FDA For Giant Cell Arteritis 10/5/2016
Ocular Therapeutix (OCUL) Begins Enrollment In First Phase 3 Clinical Trial With OTX-TP (Sustained Release Travoprost) For The Treatment Of Glaucoma And Ocular Hypertension 10/5/2016
infirst Healthcare Announces Positive Phase III Results Of Its Lipid Formulated Ibuprofen Capsules (BC1054) 10/4/2016
Dipexium Pharmaceuticals (DPRX) Receives EMA Designation As A Small And Medium Enterprise 10/4/2016
MorphoSys AG Announces That Its Licensee Janssen R&D Reports Positive Results From A Phase 3 Study Of Guselkumab In Plaque Psoriasis 10/4/2016
FDA Grants Breakthrough Therapy Designation For Genentech (Hillsboro) (RHHBY)’s Alecensa (Alectinib) For First-Line Treatment Of People With ALK-Positive NSCLC 10/4/2016
Chugai Pharma's Alecensa Receives Breakthrough Therapy Designation From FDA For First-Line Treatment Of ALK Positive Non-Small Cell Lung Cancer 10/4/2016
AbbVie (ABBV) Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual And Non-Menstrual Pelvic Pain Associated With Endometriosis At The American Society for Reproductive Medicine Scientific Congress 10/4/2016
Regeneron (REGN), Sanofi (SNY) Tout Phase III Dupixent Data 10/3/2016
Johnson & Johnson (JNJ) Psoriasis Drug Tops Placebo, Humira In Late Stage Study 10/3/2016
Boston's Albireo Reports Positive Late Stage Data Results for Elobixibat 10/3/2016
Bay Area Dermira (DERM)'s CImzia Meets Co-Primary Endpoints in Key Phase III Study 10/3/2016
Janssen R&D Release: New Phase 3 Data Show Significant Efficacy Versus Placebo And Superiority Of Guselkumab Versus Humira In Treatment Of Moderate To Severe Plaque Psoriasis 10/3/2016
Spectral (EDTXF)'s Sepsis Device Flunks Late-Stage Trial 10/3/2016
Johnson & Johnson (JNJ) Allegedly Failed to Disclose Faulty Device Concerns in Xarelto Trial 9/30/2016
Braeburn Pharma And Camurus Enroll First Patients In A Phase 3 Efficacy Trial Of CAM2038 For Treatment Of Chronic Low Back Pain 9/30/2016
Orbus Therapeutics Selects DSG, Inc. For EDC And IWRS In Recurrent Anaplastic Astrocytoma Clinical Study 9/30/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Joint Venture Initiates Second Phase 3 Study Of RGN-259 For Dry Eye Syndrome 9/30/2016
Eisai Inc. (ESALF.PK) Release: Now Enrolling: Global Phase 3 Clinical Trial To Evaluate Potential First-Line Use Of Lenvatinib In Combination With Pembrolizumab Or Everolimus For Patients With Advanced Renal Cell Carcinoma 9/29/2016
FDA Slaps Clinical Hold on Alcobra (ADHD)'s Late Stage ADHD Study 9/29/2016
Amgen (AMGN), Novartis AG (NVS)'s Migraine Drug Successful in Phase III Study 9/29/2016
Intra-Cellular Therapies's Future Up in the Air as Stock Plunges After Schizophrenia Study Fails 9/29/2016
Sarepta (SRPT) Announces First Patient Dosed In Phase III Clinical Trial Of SRP-4045 And SRP-4053 For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 45 Or 53 Skipping 9/29/2016
Collegium (COLL) Announces Publication Of Data On Oral Abuse Potential Of Xtampza ER 9/29/2016
Novan Announces Both SB204 Phase 3 Pivotal Trials Fully Enrolled 9/28/2016
Dermira (DERM) To Present Data From DRM04 Phase III Clinical Trials At Late-Breaking News Session At European Academy Of Dermatology And Venereology Congress 9/28/2016
Moberg Pharma AB (Formerly known as Moberg Derma) Begins Patient Enrollment In North America And Europe In Two Phase 3 Studies Of MOB-015 In Onychomycosis 9/28/2016
Two New Trials Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) As Monotherapy And In Combination With Chemotherapy For First-Line Treatment Of Patients With Advanced Non-Small Cell Lung Cancer To Be Presented During Presidential Session At ESMO 2016 9/28/2016
Pfizer (PFE) To Showcase Progress Of Broad-Based Oncology Portfolio At European Society For Medical Oncology (ESMO) 2016 Congress 9/28/2016
Celgene (CELG) Release: Oral OTEZLA (Apremilast) Long-Term Safety Data Presented At EADV Congress In Both Psoriasis And Psoriatic Arthritis 9/28/2016
Galapagos (GLPG.BR) Release: Successful Completion Of Regulatory Consultations To Progress Filgotinib To Phase 3 In Inflammatory Bowel Disease 9/28/2016
Eleventa Announce Completion Of Patient Enrollment In Phase 3 Clinical Trial Of CRTH2 Antagonist Timapiprant For The Treatment Of Allergic Asthma 9/28/2016
Amgen (AMGN) Hit With a Setback as Krypolis Fails to Help Newly Diagnosed Multiple Myeloma Patients 9/27/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Studies Of JZP-110 Evaluating Excessive Sleepiness In Obstructive Sleep Apnea 9/27/2016
AcelRx (ACRX) Initiates Phase 3 Study Of Zalviso In Patients With Moderate-To-Severe Acute Post-Operative Pain 9/27/2016
Kitov (KTOV) Reports Successful Results For Additional KIT-302 Pharmacokinetic Bioequivalence Study 9/27/2016
FDA Slaps Clinical Hold on CEL-SCI (CVM)’s Head and Neck Cancer Study 9/27/2016
CEL-SCI (CVM) Reports Clinical Hold On Head And Neck Cancer Study 9/27/2016
Array BioPharma (ARRY) Rockets as Melanoma Drug Meets Endpoint in Phase III Study 9/26/2016
SciClone (SCLN) Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market 9/26/2016
GW Pharma (GWPH)'s Cannabis-Derived Drug Successful in Third Late-Stage Epilepsy Study 9/26/2016
Akebia (AKBA) Announces Publication Highlighting Potential Benefits Of HIF Treatments For Patients With Renal Anemia 9/26/2016
Orbus Therapeutics Announces Enrollment Of First Patient In Phase 3 Trial In Late-Stage Brain Cancer 9/26/2016
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study 9/23/2016
This Biotech Has the Upper Hand Over Allergan (AGN) and Gilead (GILD) in the Heated Nash Battle 9/23/2016
Gilead (GILD) Terminates Phase II/III Study of Ulcerative Colitis Drug 9/23/2016
Findings From AcelRx (ACRX)' Phase 3 SAP301 Study Of ARX-04 In Abdominoplasty Patients To Be Presented At Plastic Surgery Meeting 9/23/2016
Enanta Pharmaceuticals, Inc. Announces Data On Eight-Week Treatment Of AbbVie (ABBV)’s VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C 9/23/2016
AbbVie (ABBV) Presents Data On Eight-Week Treatment Of VIEKIRAX (Ombitasvir/Paritaprevir/Ritonavir Tablets) + EXVIERA (Dasabuvir Tablets) In Patients With Genotype 1b Chronic Hepatitis C 9/23/2016
Armed With Fresh Phase III Data, Novartis AG (NVS) Eyes First-Line Use for Lung Cancer Drug Zykadia 9/23/2016
H. Lundbeck A/S (LUN.CO)'s Phase III Data Crushes Hope for Alzheimer’s Once Again 9/23/2016
Pharma Bro Warned You: Mast Therapeutics (MSTX) Craters After Drug Flunks Phase III Test, Job Cuts Expected 9/22/2016
Sanaria Inc. PfSPZ Vaccine Against Malaria Receives D&A Pharma Fast Track Designation 9/22/2016
PharmaMar Submits MAA To EMA For Aplidin For The Treatment Of Multiple Myeloma 9/22/2016
CureMark Release: Blüm Study - A Phase 3 Clinical Trial For Children With Autism 9/22/2016
Antares Pharma (ATRS) Announces Completion Of The Quickshot Testosterone Clinical Program 9/22/2016
Teva (TEVA) Announces Positive Top-Line Data From Second Phase III Study Of SD-809 In Tardive Dyskinesia (TD) 9/22/2016
Aradigm Corporation (ARDM) Announces Last Patient Dosing Visit In ORBIT-3 And ORBIT-4 Phase 3 Studies Of Pulmaquin In Non-Cystic Fibrosis Bronchiectasis Patients 9/22/2016
Aimmune (AIMT) Completes And Exceeds North American Enrollment Target Ahead Of Schedule In Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy; Company Accelerates Plans For Real-World Experience Study In The U.S. 9/21/2016
Peregrine (PPHM) Provides Update On Oral Presentation Of Top-Line Data From Phase III SUNRISE Trial Of Bavituximab At European Society For Medical Oncology (ESMO) 2016 Congress 9/21/2016
Adamas Pharma (ADMS) Announces Results Of EASE LID 3, A Pivotal Trial Of ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinson’s Disease Patients At The 4th World Parkinson Congress 9/21/2016
The Drugmaker That Could Knock Gilead (GILD) Off Its HIV Throne 9/20/2016
How Ionis Pharma (IONS) is Beating the Pants Off of Competitors Like Alnylam (ALNY), Arrowhead Pharma (ARWR) and Moderna 9/20/2016
Will Biogen (BIIB)’s Alzheimer’s Drug Be a Miracle Drug or Just Another Bomb? 9/20/2016
Biofrontera AG Completes Patient Recruitment Of Phase III Trial Of Ameluz In Combination With Daylight-PDT 9/20/2016
Another Good Day for Amgen (AMGN) as Repatha Phase III GLAGOV Trial Met Primary, Secondary Endpoints 9/20/2016
Amgen (AMGN), UCB Group (UCBJF.PK)'s Romosozumab Showed Significant Results in Phase III Study 9/19/2016
Novavax (NVAX) Stayin' Alive After Shares Crater on Flunked Phase III 9/19/2016
Diffusion Pharma Successfully Completes Animal Toxicity Studies In Preparation For Phase III Pivotal Trial Of TSC In New Diagnosed Glioblastoma Patients 9/19/2016
CoLucid Pharma (CLCD) Provides Interim Update On GLADIATOR 9/19/2016
SELLAS Life Sciences Group Receives FDA Fast Track Designation Of Galinpepimut-S For The Treatment Of Malignant Pleural Mesothelioma 9/19/2016
Quark Pharmaceuticals Inc. Chief Scientist Provides An Overview Of The Company's Clinical And Nonclinical Pipelines 9/19/2016
FDA Takes Back Special Protocol Assessment for Active Biotech (BTPC)'s Laquinimod 9/19/2016
Radius Health (RDUS) Announces Publication Of Additional Positive Results From The Phase 3 ACTIVE Trial Of Abaloparatide-SC In JBMR 9/19/2016
Pfizer (PFE) Announces Positive Top-Line Results From REFLECTIONS B537-02 Study For PF-06438179 (Infliximab-Pfizer) A Potential Biosimilar To Remicade (Infliximab) 9/19/2016
CoLucid Pharma (CLCD) Announces Achievement Of Secondary Endpoints In SAMURAI 9/19/2016
Novartis AG (NVS) Drug For Multiple Sclerosis Shows Reduction In Risks 9/19/2016
CHMP Recommends Approval Of Eli Lilly (LLY)'s Olaratumab, In Combination With Doxorubicin, For Advanced Soft Tissue Sarcoma 9/16/2016
Amgen (AMGN) Receives Positive CHMP Opinion For Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis 9/16/2016
Novo Nordisk A/S (NVO)'s New Diabetes Med Semaglutide Slashes Heart Disease Risk 9/16/2016
Takeda Pharmaceutical Co. Ltd. (TKPYY) Release: Favorable Benefit: Risk Profile For Vedolizumab As Induction And Maintenance Therapy In TNF-Naïve Or TNF-Failure Patients With Moderately To Severely Active Ulcerative Colitis Published In Clinical Gastroenterology And Hepatology 9/16/2016
Merck & Co. (MRK) Presents New Data Examining Durable Efficacy With Investigational Cladribine Tablets In Multiple Sclerosis 9/16/2016
AstraZeneca PLC (AZN) Release: Phase III Combination Trial Of BYDUREON And FARXIGA Shows Significant Blood Sugar Reduction In Patients With Type 2 Diabetes 9/16/2016
Pfizer (PFE) Receives Positive CHMP Opinion For IBRANCE (Palbociclib) In Combination With Endocrine Therapy For The Treatment Of HR+/HER2- Metastatic Breast Cancer In Europe 9/16/2016
Treatment Effects Maintained Over Six Years In Patients With Relapsing Remitting Multiple Sclerosis Who Received Sanofi Genzyme (SNY)’s Lemtrada (Alemtuzumab) In Clinical Trials 9/16/2016
OptiNose AS Presents Data From Phase III Trials With Investigational Product Using Exhalation Delivery System Technology For Treatment In Patients With Chronic Rhinosinusitis (CRS) With And Without Nasal Polyps 9/16/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year 9/16/2016
SoCal's Aerie (AERI) Stock Soars Over the Rainbow on Positive Phase III Eye Drug Data 9/16/2016
AcelRx (ACRX) Surges as Pain Drug is Found Safe in Final Late-Stage Study 9/15/2016
Otonomy (OTIC) Successfully Completes Open-Label Clinical Trial For OTIPRIO In Patients With History Of Otitis Media Requiring Tympanostomy Tubes 9/15/2016
GlaxoSmithKline (GSK)'s Experimental Shingles Vaccine 90% Effective in People Over Age 70 9/15/2016
Merck & Co. (MRK), Pfizer (PFE)'s Diabetes Candidate Meets Late-Stage Study Goals 9/15/2016
Intarcia Completes First Close Of A Major Equity Financing; Poised For ITCA 650 NDA Filing For Type 2 Diabetes, Commercial Readiness And Pipeline Progression 9/15/2016
Results From 1,000-Patient, Global Real-World Patient-Reported Outcomes Study Of Sanofi Genzyme (SNY)’s Aubagio (Teriflunomide) In Patients With Relapsing Multiple Sclerosis Demonstrate High Levels Of Treatment Satisfaction 9/15/2016
Innovent Biologics Starts China Trials of Two Biologic Drug Candidates 9/15/2016
Acasti Pharma Reports Positive CaPre Omega-3 Bridging Study Data 9/15/2016
AbbVie (ABBV) And Biogen (BIIB) Release: New Data Presented At ECTRIMS Reinforce Efficacy Of ZINBRYTA (Daclizumab) And Support Long-Term Safety Profile 9/15/2016
Biogen (BIIB) Shows Off New Tecfidera Data in MS Trials 9/14/2016
Genentech (RHHBY) Release: Phase III Efficacy Results Of Investigational Medicine OCREVUS (Ocrelizumab) Reinforced By Exploratory Analyses In Two Forms Of Multiple Sclerosis 9/14/2016
Eisai Inc. (ESALF.PK) Announces New FYCOMPA (Perampanel) Data Presented At The 12th European Congress On Epileptology (ECE) 9/14/2016
Will FDA’s Scrutiny of Pfizer (PFE)’s Chantix Trial Go Up in Smoke? 9/13/2016
10 Biotechs—Count ‘Em, 10!—With Big Decisions in the Fourth Quarter 9/13/2016
Citius Pharma Initiates Mino-Lok Phase 3 Trial 9/13/2016
Can-Fite BioPharma (CFBI) Receives Notice Of Allowance For Psoriasis Patent In Europe Ahead Of Phase III Trial 9/13/2016
Portola (PTLA) Announces Upcoming Data Presentations On Andexxa (Andexanet Alfa) At Neurocritical Care Society 2016 Annual Meeting 9/13/2016
Adamas Pharma (ADMS) Announces Two Data Presentations On ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) At The 4th World Parkinson Congress 9/13/2016
Lexicon Pharma (LXRX) Rockets on Late-Stage Diabetes Drug Data 9/12/2016
Angionetics' Generx [Ad5fgf-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease 9/12/2016
Cytokinetics (CYTK) Announces Additional Results From COSMIC-HF To Be Presented At The HFSA Annual Scientific Meeting 9/12/2016